TTThuy A. Tran

Thuy A. Tran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thuy A. Tran has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Orlova

    Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden

    3 shared publications
  • Vladimir Tolmachev

    UNIIM – Affiliated branch of the D. I. Mendeleyev Institute for Metrology

    3 shared publications
  • Amelie Eriksson Karlström

    Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Medical Radiation Physics, Uppsala University Hospital, and Department of Medical Sciences, Uppsala University, Uppsala, Sweden, School of Biotechnology, Division of Molecular Biotechnology, Royal Institute of Technology, Stockholm, Sweden, and Affibody AB, Bromma, Sweden

    2 shared publications
  • Lars Abrahmsén

    Affibody AB, Bromma, Sweden

    2 shared publications
  • Mattias Sandström

    Hospital Physics, Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

    2 shared publications
  • Alexander Bruskin

    Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Sweden, School of Biotechnology, Division of Molecular Biotechnology, Royal Institute of Technology, Stockholm, Sweden, Affibody AB, Bromma, Sweden, Hospital Physics, Department of Oncology, Uppsala University Hospital, Uppsala, Sweden, and Russian Research Centrum, Institute of Biophysics, Moscow, Russia

    1 shared publication

Latest Publications

  • Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging

    by Thuy A. Tran, Daniel Rosik, Lars Abrahmsén, Mattias Sandström, Anna Sjöberg, Helena Wållberg, Sara Ahlgren, Anna Orlova, Vladimir Tolmachev

    Purpose The purpose of this study was to design and evaluate a novel platform for labelling of Affibody molecules, enabling both recombinant and synthetic production and site-specific labelling with 99mTc or trivalent radiometals. Methods The HER2-specific Affibody molecule PEP05352 was made by peptide synthesis. The chelator sequence SECG (serine-glutamic acid-cysteine-glycine) was anchored on the C-terminal to allow 99mTc labelling. The cysteine can alternatively serve as a conjugation site of the chelator DOTA for indium labelling. The resulting 99mTc- and 111In-labelled Affibody molecules were evaluated both in vitro and in vivo. Results Both conjugates retained their capacity to bind to HER2 receptors in vitro and in vivo. The tumour to blood ratio in LS174T xenografts was 30 at 4 h post-injection for both conjugates. Biodistribution data showed that the 99mTc-labelled Affibody molecule had a fourfold lower kidney accumulation compared with the 111In-labelled Affibody molecule while the accumulation in other organs was similar. Gamma camera imaging of the conjugates could clearly visualise the tumours 4 h after injection. Conclusion Incorporation of the C-terminal SECG sequence in Affibody molecules provides a general multifunctional platform for site-specific labelling with different nuclides (technetium, indium, gallium, cobalt or yttrium) and for a flexible production (chemical synthesis or recombinant).


  • Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of 99mTc-Labeled Anti-HER2 Affibody Molecules

    by Thuy A. Tran, Torun Ekblad, Anna Orlova, Mattias Sandström, Joachim Feldwisch, Anders Wennborg, Lars Abrahmsén, Vladimir Tolmachev, Amelie Eriksson Karlström

    The effects of polar (mercaptoacetyl-triseryl) and negatively charged (mercaptoacetyl-triglumatyl) chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules were previously investigated. With glycine, serine, and glutamate, we demonstrated that substitution with a single amino acid in the chelator can significantly influence the biodistribution properties and the excretion pathways. Here, we have taken this investigation further, by analyzing the effects of introduction of a positive amino acid residue on the in vivo properties of the 99mTc-labeled Affibody molecule. The Affibody molecules with mercaptoacetyl-seryl-lysyl-seryl (maSKS) and mercaptoacetyl-trilysyl (maKKK) extensions were produced by peptide synthesis and labeled with 99mTc in alkaline conditions. A comparative biodistribution was performed in normal mice to evaluate the excretion pathway. A shift toward renal excretion was obtained when serine was substituted with lysine in the chelating sequence. The radioactivity in the gastrointestinal tract was reduced 3-fold for the 99mTc-maSKS-ZHER2:342 and 99mTc-maKKK-ZHER2:342 in comparison with the 99mTc-maSSS- ZHER2:342 conjugate 4 h post injection (p.i.). The radioactivity in the liver was elevated when a triple substitution of positively charged lysine was used. The tumor targeting properties of 99mTc-maSKS-ZHER2:342 were further investigated in SKOV-3 xenografts. The tumor uptake of 99mTc-maSKS-ZHER2:342 was 17 ± 7% IA/g 4 h p.i. Tumor xenografts were well-visualized by gamma scintigraphy. In conclusion, the substitution with one single lysine in the chelator results in better tumor imaging properties of the Affibody molecule ZHER2:342 and is favorable for imaging of tumors and metastases in the abdominal area. Multiple lysine residues in the chelator are, however, undesirable due to elevated uptake both in the liver and kidneys.


  • In Vivo Evaluation of Cysteine-Based Chelators for Attachment of 99mTc to Tumor-Targeting Affibody Molecules

    by Thuy Tran, Torun Engfeldt, Anna Orlova, Charles Widström, Alexander Bruskin, Vladimir Tolmachev, Amelie Eriksson Karlström

    Affibody molecules present a new class of affinity proteins, which utilizes a scaffold based on a 58-amino acid domain derived from protein A. The small (7 kDa) Affibody molecule can be selected to bind to cell-surface targets with high affinity. An Affibody molecule (ZHER2:342) with a dissociation constant (Kd) of 22 pM for binding to the HER2 receptor has been reported earlier. Preclinical and pilot clinical studies have demonstrated the utility of radiolabeled ZHER2:342 in imaging of HER2-expressing tumors. The small size and cysteine-free structure of Affibody molecules enable complete peptide synthesis and direct incorporation of radionuclide chelators. The goal of this study was to evaluate if incorporation of the natural peptide sequences cysteine-diglycine (CGG) and cysteine-triglycine (CGGG) sequences would enable labeling of Affibody molecules with 99mTc. In a model monomeric form, the chelating sequences were incorporated by peptide synthesis. The HER2-binding affinity was 280 and 250 pM for CGG-ZHER2:342 and CGGG-ZHER2:342, respectively. Conjugates were directly labeled with 99mTc with 90% efficiency and preserved the capacity to bind specifically to HER2-expressing cells. The biodistribution in normal mice showed a rapid clearance from the blood and the majority of organs (except kidneys). In the mice bearing SKOV-3 xenografts, tumor uptake of 99mTc-CGG-ZHER2:342 was HER2-specific and a tumor-to-blood ratio of 9.2 was obtained at 6 h postinjection. Gamma-camera imaging with 99mTc-CGG-ZHER2:342 clearly visualized tumors at 6 h postinjection. The results show that the use of a cysteine-based chelator enables 99mTc-labeling of Affibody molecules for imaging.